Breast Cancer Home > Femara for Breast Cancer

Femara® (letrozole) is commonly prescribed for the treatment of breast cancer. Specifically, this drug is designed for postmenopausal women who:
  • Have early breast cancer that is hormone receptor-positive and who have had surgery
  • Have taken tamoxifen (Nolvadex®, Soltamox™) for five years after surgery or radiation therapy for breast cancer
  • Have advanced or metastatic (spreading) breast cancer that is either hormone receptor-positive or hormone receptor-unknown.
Femara works by helping to decrease estrogen production in the body, which in turn causes the growth of the breast cancer cells to slow down. This means this drug is a type of hormonal therapy.
Studies have shown that switching to Femara for breast cancer treatment after taking tamoxifen for five years, compared to not taking anything after five years of tamoxifen, can reduce the chances of breast cancer recurring (coming back). It also delays the time to progression (the time between when the cancer is treated until the disease starts to get worse).
(To learn more about how this drug works to combat breast cancer, click Femara. This article also covers the results of other clinical studies, possible side effects, and more.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Topics & Medications


Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.